Back close

Dr. Nupur Das

Senior Consultant, Department of Pathology, School of Medicine, Faridabad | Assistant Professor, Department of Pathology, School of Medicine, Faridabad

Qualification: MBBS, MD

Bio

Dr. Nupur Das is an accomplished hematopathologist with 9 years of experience post MD. She has served as Assistant Professor of Laboratory Oncology services at National Cancer Institute (NCI), AIIMS, Jhajjar campus. She did her MBBS and MD from King George Medical University, Lucknow. She further completed her three Senior Residency programme from AIIMS, New Delhi. Due to her keen interest in academics and research, she also served as senior research fellow at AIIMS, Delhi and was awarded twice during her SRship tenure.

She is a Core Hematopathologist with 9 years of experience in diagnostic hematology including design, optimization, standardization, and validation of multiparametric flowcytometry in various hematological malignancies. She also has vast experience of clinical analysis of cytogenetics, FISH and molecular techniques including NGS in hemato-oncology. She has the experience of the establishment and successfully running a fully automated clinical core laboratory at NCI, AIIMS, Jhajjar.

Qualification

  1. MD – Pathology; King Georges Medical University, Lucknow
  2. MBBS – King Georges Medical University, Lucknow

Languages Known

  • Hindi
  • English
Publications

Journal Article

Year : 2023

Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

Cite this Research Publication : Das N & Gupta R. (2023). Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry. Indian Journal of Medical and Paediatric Oncology. 10.1055/s-0043-1768176

Publisher : Indian Journal of Medical and Paediatric Oncology

Year : 2023

Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

Cite this Research Publication : Das N, Dahiya M, Gupta R, Kumar L, Rani L, Gupta A, Farswan A, Sharma A, Sharma OD. Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. Am J Clin Pathol. 2023 Jan 4; 159(1):69-80. doi: 10.1093/ajcp/aqac129. PMID: 36317501

Publisher : Am J Clin Pathol.

Year : 2023

The Evaluation of Laboratory Parameters as Predictors of Disease Severity and Mortality in COVID-19 Patients: A Retrospective Study from a Tertiary Care Hospital in India

Cite this Research Publication : Dwivedi T, Raj A, Das N, Gupta R, Gupta N, Tiwari P, Sahoo B, Sagiraju H K R, Sirohiya P, Ratre B, Elavarasi A, Mohan A & Bhatnagar S. (2023). The Evaluation of Laboratory Parameters as Predictors of Disease Severity and Mortality in COVID-19 Patients: A Retrospective Study from a Tertiary Care Hospital in India. Cureus. 10.7759/cureus.40273

Publisher : Cureus

Year : 2022

Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? -A retrospective cohort study

Cite this Research Publication : Sirohiya P, Elavarasi A, Sagiraju HKR, Baruah M, Gupta N, Garg RK, Paul SS, Ratre BK, Singh R, Kumar B, Vig S, Pandit A, Kumar A, Garg R, Meena VP, Mittal S, Pahuja S, Das N, Dwivedi T, Gupta R, Kumar S, Pandey M, Mishra A, Matharoo KS, Mohan A, Guleria R, Bhatnagar S. Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? -A retrospective cohort study. Lung India. 2022 May-Jun; 39(3):247-253. doi: 10.4103/lungindia.lungindia_601_21. PMID: 35488682; PMCID: PMC9200195

Publisher : Lung India

Year : 2022

Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with patternbased recognition

Cite this Research Publication : Das N, Dahiya M, Gupta R, Rai S, Singh S, Prajapati VK, Kumar L, Sharma A, Sahoo RK, Gogia A. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with patternbased recognition. Cytometry B Clin Cytom. 2022 Jul; 102(4):292-302. doi: 10.1002/cyto.b.22062. Epub 2022 Feb 25. PMID: 35212134

Publisher : Cytometry B Clin Cytom

Year : 2022

Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders

Cite this Research Publication : Jain G, Das N, Gajendra S, et al. Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. Int J Lab Hematol. 2022; 1- 9. doi:10.1111/ijlh.13887

Publisher : Int J Lab Hematol

Year : 2022

Genomic landscape of mature B-cell non-Hodgkin lymphomas – An appraisal from lymphomagenesis to drug resistance

Cite this Research Publication : Panda D, Das N, Thakral D, Gupta R. Genomic landscape of mature B-cell non-Hodgkin lymphomas - An appraisal from lymphomagenesis to drug resistance. Journal of the Egyptian National Cancer Institute. 2022- Accepted

Publisher : Journal of the Egyptian National Cancer Institute

Year : 2022

Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma

Cite this Research Publication : Das N, Dahiya M, Gupta R, Kumar L, Sharma A, Rai S, Singh S, Prajapati VK, Sahoo RK, Gogia A. Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma. Cytometry B Clin Cytom. 2022 May; 102(3):209-219. doi: 10.1002/cyto.b.22068. Epub 2022 Apr 7. PMID: 35389550

Publisher : Cytometry B Clin Cytom

Year : 2022

Utility of CD229 as novel marker in measurable residual disease assessment in Multiple Myeloma – an evidence-based approach

Cite this Research Publication : Rai S*, Das N*, Gupta R, Kumar L, Sharma A, Singh S, Prajapati VK. Utility of CD229 as novel marker in measurable residual disease assessment in Multiple Myeloma - an evidence-based approach. Int J Lab Hematol. 2022- Accepted

Publisher : Int J Lab Hematol

Year : 2021

The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death – real-world data from a cohort of patients hospitalized with COVID-19

Cite this Research Publication : Sagiraju H R, Elavarasi A, Gupta N, Kumar R, Paul S S, Vig S, Sirohiya P & Ratre B, Garg R, Pandit A, Singh R, Kumar B, Meena V, Wig N, Mittal S, Pahuja S, Madan K, Das N, Dwivedi T, Bhatnagar S. The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death – real-world data from a cohort of patients hospitalized with COVID-19. medRxiv 2021.08.26.21262705

Publisher : medRxiv

Year : 2021

Evaluation of Immunophenotype of the Non-Neoplastic Plasma Cell Compartment and Post-Therapy Immunomodulation to Understand Nuances in MRD Assessment of Multiple Myeloma Using Next-Generation Flow Cytometry

Cite this Research Publication : Gupta R, Das N, Dahiya M, Rai S, Singh S, Prajapati V, Sahoo R, Gogia A, Sharma A, Kumar L. Evaluation of Immunophenotype of the Non-Neoplastic Plasma Cell Compartment and Post-Therapy Immunomodulation to Understand Nuances in MRD Assessment of Multiple Myeloma Using Next-Generation Flow Cytometry. Clin Lymphoma Myeloma Leuk. 2021; 21. S436- S437

Publisher : Clin Lymphoma Myeloma Leuk

Year : 2021

Pattern-Based Identification of Normal and Aberrant Plasma Cell Compartment across a Spectrum of Plasma Cell Proliferative Disorders Using Multiparametric Flow Cytometry.

Cite this Research Publication : Das N, Gupta R, Dahiya M, Rai S, Singh S, Prajapati VK, Sahoo RK, Gogia A, Sharma A, Kumar L. Pattern-Based Identification of Normal and Aberrant Plasma Cell Compartment across a Spectrum of Plasma Cell Proliferative Disorders Using Multiparametric Flow Cytometry. Clin Lymphoma Myeloma Leuk. 2021; 21(1): S438. ISSN 2152-2650

Publisher : Clin Lymphoma Myeloma Leuk

Year : 2021

Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL

Cite this Research Publication : Das N, Gupta R, Gupta SK, Bakhshi S, Seth R, Kumar C, Rai S, Singh S, Prajapati VK, Gogia A, Sahoo RK, Sharma A, Kumar L. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL. Ann Hematol. 2021 Oct; 100(10):2487-2500. doi: 10.1007/s00277-021-04580-2. Epub 2021 Jul 8. PMID: 34236495

Publisher : Ann Hematol

Year : 2020

A Realworld Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML

Cite this Research Publication : Das N, Gupta R, Gupta SK, Bakhshi S, Malhotra A, Rai S, Singh S, Prajapati VK, Sahoo RK, Gogia A, Sharma A, Kumar L. A Realworld Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. Clin Lymphoma Myeloma Leuk. 2020 Oct; 20(10): e673-e684. doi: 10.1016/j.clml.2020.05.004. Epub 2020 May 11. PMID: 32561191

Publisher : Clin Lymphoma Myeloma Leuk

Year : 2020

Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?

Cite this Research Publication : Thakral D*, Das N*, Basnal A, Gupta R. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet? Am J Blood Res. 2020 Jun 15; 10(3):26-45. PMID: 32685257; PMCID: PMC7364270

Publisher : Am J Blood Res

Year : 2019

To explore the utility of diagnostic immunophenotypes for detection of MRD in B ALL

Cite this Research Publication : Das N, Gupta Ritu, Malhotra Ankit, Rai Sandeep, Gupta Sanjeev, Singh Saroj, Sahoo Ranjit, Gogia Ajay, Bakhshi Sameer, Kumar Lalit. To explore the utility of diagnostic immunophenotypes for detection of MRD in B ALL - Indian Journal of Hematol and Blood Transfusion (2019) 35: S26

Publisher : Indian Journal of Hematol and Blood Transfusion

Year : 2019

Role of CD123 as Determinant of Minimal Residual Disease in Acute Myeloid Leukemia

Cite this Research Publication : Das N, Malhotra Ankit, Gupta Ritu, Rai Sandeep, Gupta Sanjeev, Singh Saroj, Sahoo Ranjit, Gogia Ajay, Bakhshi Sameer, Kumar Lalit. (2019). Role of CD123 as Determinant of Minimal Residual Disease in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 19. S235. https://doi.org/10.1016/j.clml.2019.07.123

Publisher : Clin Lymphoma Myeloma Leuk.

Year : 2019

CD123 is an Important Predictor of Post Induction Response and Early Treatment Outcome in Acute Lymphoblastic Leukemia

Cite this Research Publication : Das N, Malhotra A, Gupta Ritu, Rai Sandeep, Gupta Sanjeev, Sahoo Ranjit, Gogia Ajay, Bakhshi Sameer, Kumar Lalit, Singh Saroj. (2019). CD123 is an Important Predictor of Post Induction Response and Early Treatment Outcome in Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 19. S197

Publisher : Clin Lymphoma Myeloma Leuk

Year : 2019

FLI1 and MIC2 expression in precursor B-lymphoblastic leukemia with Burkitt-like morphology and extensive extramedullary involvement: A diagnostic challenge in pediatric small round cell tumor

Cite this Research Publication : Das N, Thakral D, Singh G, Malhotra A, Phulware RH, Gogia A, Gupta R. FLI1 and MIC2 expression in precursor B-lymphoblastic leukemia with Burkitt-like morphology and extensive extramedullary involvement: A diagnostic challenge in pediatric small round cell tumor. Indian J Pathol Microbiol. 2019 Oct-Dec;62(4):614-617. doi: 10.4103/IJPM.IJPM_520_18. PMID: 31611454

Publisher : Indian J Pathol Microbiol

Conference Paper

Year : 2020

Clinical implications of post therapy immunomodulation in multiple myeloma assessed by flowcytometry

Cite this Research Publication : Das N, Dahiya M, Gupta R, Kumar L, Sharma A, Rai S, Singh S, Prajapati VK, Sahoo RK, Gogia A. Clinical implications of post therapy immunomodulation in multiple myeloma assessed by flowcytometry - 61st Annual conference of Indian Society of Hematology and Blood transfusion. (Nov 2020) 36 (Suppl1)

Publisher : 61st Annual conference of Indian Society of Hematology and Blood transfusion

Area of Expertise
  • Multiparametric Flowcytometry & Cell Sorting
  • Conventional Cytogenetics and FISH in malignant hematology
  • Molecular techniques including NGS in hemat-oncology
Work Experience
  1. NCI – AIIMS, Jhajjar From Oct 2020 to Present; Position: Assistant Professor, Laboratory Oncology AIIMS, Delhi
  2. From Sep 2019 to Sep, 2020, Position: Sr. Research Fellow, Laboratory Oncology, Dr BRAIRCH AIIMS, Delhi
  3. From Sep 2016 to Sep 2019, Position: Sr. Resident, Laboratory Oncology, Dr BRAIRCH AIIMS, Delhi
Awards and Recognitions
  1. 2022 –TCS Annual Conference (The Flow-cytometry Society Of India) – Best paper of the year in clinical science category
  2. 2020 – ESH Young Fellow Scholarship – 5th Translational Research E-Conference on Multiple Myloma
  3. 2019 – AIIMS International Travel Grant for SOHO 2019
  4. 2019 – First Prize for Oral Paper at First Annual Research Day of AIIMS, N. Delhi
  5. 2018- TCS Annual Conference -Best Oral Paper award
Admissions Apply Now